Get started
Author

Calvin Jia

Observed name: Jia, Calvin
ORCID: 0000-0001-8732-6035
Observed ORCID: 0000-0001-8732-6035
OpenAlex ID: A5069504663
Phase 3 KEYNOTE-905/EV-303: Perioperative pembrolizumab (pembro) or pembro + enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).
2023 · Andrea Necchi, Jens Bedke, et al. · Journal of Clinical Oncology · 25
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
2024 · Irfan Cicin, Elizabeth R. Plimack, et al. · BMC Cancer · 23
KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).
2021 · Matt D. Galsky, Andrea Necchi, et al. · Journal of Clinical Oncology · 22
First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.
2022 · Yohann Loriot, Petros Grivas, et al. · Journal of Clinical Oncology · 19
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study
2024 · Andrea Necchi, Michiel S. Van der Heijden, et al. · BMC Cancer · 17
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B
2025 · Keun-Wook Lee, Devalingam Mahalingam, et al. · Nature Communications · 14
PDF
KEYNOTE-905/EV-303: A phase 3 study to evaluate the efficacy and safety of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).
2023 · Andrea Necchi, Jens Bedke, et al. · Journal of Clinical Oncology · 5
PDF
Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-line Therapy for Advanced Colorectal Adenocarcinoma: The Phase II DeFianCe Trial
2026 · Zev A. Wainberg, Keun-Wook Lee, et al. · Clinical Cancer Research · 1
Abstract 7715: Elevated baseline DKK1 plasma is a biomarker for sirexatamab treated colorectal cancer patients
2026 · Zongzhong Tong, Scott Patton, et al. · Cancer Research
Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B
2026 · Keun-Wook Lee, Devalingam Mahalingam, et al. · Nature Communications
PDF
Family-wise type I error rate control for an extended 2-in-1 design with graphical approach in oncology drug development
2022 · Wen Li, Heng Zhou, et al. · Contemporary Clinical Trials
Works count: 17
Citation count: 126
H-index: 6
I10-index: 6
Year
Topic
Type